Table 1. Response criteria categories.

Response	mRECIST: Unidirectional Ax measurement	EASL: Bidirectional Ax measurement	qEASL: Volumetric measurement
Progressive Disease (PD)	20% increase in size or new lesion	25% increase in size or new lesion	25% increase in size or new lesion
Stable Disease (SD)	Neither PR nor PD criteria met	Neither PR nor PD	Neither PR nor PD
Partial Response (PR)	30% decrease in size	50% decrease in size	50% decrease in size
Complete Response (CR)	No residual area of disease	No residual area of disease	No residual area of disease

Abbreviations: Ax, axial; EASL, European association for the study of the liver; mRECIST, modified response evaluation criteria in solid tumors; qEASL, quantitative EASL.